IGHE and leukemia: To further evaluate CD23 competition on cells, we measured ligelizumab- and omalizumab-mediated inhibition of IgE-binding to CD23 by flow cytometry using the CD19-/CD23-expressing leukemia B-cell line RPMI8866 (Fig. 2e).